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Hereditary nonpolyposis colorectal cancer (HNPCC) is caused by mutations in the mismatch-repair genes. We
report here the identification and characterization of a founder mutation in MSH2 in the Ashkenazi Jewish pop-
ulation. We identified a nucleotide substitution, MSH2*1906GrC, which results in a substitution of proline for
alanine at codon 636 in the MSH2 protein. This allele was identified in 15 unrelated Ashkenazi Jewish families
with HNPCC, most of which meet the Amsterdam criteria. Genotype analysis of 18 polymorphic loci within and
flanking MSH2 suggested a single origin for the mutation. All colorectal cancers tested showed microsatellite
instability and absence of MSH2 protein, by immunohistochemical analysis. In an analysis of a population-based
incident series of 686 Ashkenazi Jews from Israel who have colorectal cancer, we identified 3 (0.44%) mutation
carriers. Persons with a family history of colorectal or endometrial cancer were more likely to carry the mutation
than were those without such a family history ( ), and those with colorectal cancer who carried themutationPp .042
were, on average, younger than affected individuals who did not carry it ( ). The mutation was not detectedPp .033
in either 566 unaffected Ashkenazi Jews from Israel or 1,022 control individuals from New York. In hospital-based
series, the 1906C allele was identified in 5/463 Ashkenazi Jews with colorectal cancer, in 2/197 with endometrial
cancer, and in 0/83 with ovarian cancer. When families identified by family history and in case series are included,
25 apparently unrelated Ashkenazi Jewish families have been found to harbor this mutation. Although this path-
ogenic mutation is not frequent in the Ashkenazi Jewish population (accounting for 2%–3% of colorectal cancer
in those whose age at diagnosis is !60 years), it is highly penetrant and accounts for approximately one-third of
HNPCC in Ashkenazi Jewish families that fulfill the Amsterdam criteria.
Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC)
(MIM 114500) is the most common hereditary colorec-
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tal cancer syndrome, accounting for ∼2% of incident
cases (Aaltonen et al. 1998; Peltomaki 2001). When es-
tablished family history criteria, known as “the Am-
sterdam criteria” (Vasen et al. 1991, 1999), are used to
ascertain families as affected with HNPCC, disease-caus-
ing mutations in the mismatch-repair genes MLH1
(MIM 120436) and MSH2 (MIM 120435) are identified
in 50%–80% of the families (Peltomaki 2001). In certain
populations, founder mutations explain a substantial
fraction of HNPCC. For example, in Finland, two mu-
tations in MLH1 (a 3.5-kb genomic deletion affecting
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Table 2
Clinical and laboratory Data on Ashkenazi Jewish Families That Meet Amsterdam Criteria 1 or 2
INDIVIDUAL KINDRED MSI
1906 C
ALLELE
OTHER MISMATCH-
REPAIR MUTATIONS
NO. OF
CRCs
Other HNPCC-
Related Cancers
1 175 Present Present None detected 5 1
2 284 Present Absent Not tested 4 0
3 1580 Present Present Not detected 3 4
4 1614 Absenta Absent None detected 3 1
5 1692 Present Present Not tested 5 0
6 1915 Absent Absent Not tested 3 0
7 2101 Absent Absent Not tested 3 0
8 2650 Present Present Absent 3 3
9 3051 Not tested Absent MLH1*1411del4 3 1
10 3274 Present Absent MSH6*3987insGTCA 3 0
11 3571 Not tested Absent Not tested 6 0
12 3762 Not tested Absent Not tested 7 0
NOTE.—All families were ascertained at MSKCC during 1995–2001.
a The tissue tested for MSI in these families consisted of adenomatous polyps: in kindred 1614, a polyp
was tested in the proband, and analysis of MLH1 and MSH2 was performed; in kindred 3762, one
adenomatous polyp was tested. MSI-H was not detected.
exon 16, known as “mutation 1,” and a splice-acceptor
site mutation of exon 6, known as “mutation 2”) ac-
count for 63% of all disease-causing mutations identified
in families with HNPCC (Nystrom-Lahti et al. 1995;
Moisio et al. 1996). Mutations 1 and 2 have been cal-
culated to have originated 16–43 and 5–21 generations
ago, respectively. A Swiss group identified an MLH1
mutation (MLH1*2141GrA, resulting in the substitu-
tion W714X, in several apparently unrelated families
from the Valais region of Switzerland. Haplotype anal-
ysis indicates that this is a founder mutation, although
the age of the mutation could not be precisely deter-
mined (Hutter et al. 1996). Another possible founder
mutation, an 1.8-kb deletion involving exon 11 of
MLH1, resulting in an mRNA transcript with a deletion
of exons 10–11, has been reported in China (Chan et
al. 2001). Recent haplotype studies of the recurrent
MSH2 mutation (MSH2*IVS53ArT), which disrupts
the 3′ splice site of exon 5, leading to the deletion of this
exon from the MSH2 mRNA, confirm that the mutation
has multiple origins but is a founder mutation in New-
foundland, Canada (Desai et al. 2000). To our knowl-
edge, no other founder mutations in MSH2 have been
reported. The identification of founder mutations not
only is of research interest but has practical implications,
in that ethnic-specific mutation analysis can be offered
before a more general search for disease-associated mu-
tations is attempted. This approach has been particularly
successful when genetic testing for BRCA1/2 is offered
to the Ashkenazi Jewish population, in which three foun-
der mutations account for the majority of all BRCA1/2
mutations (Shiri-Sverdlov et al. 2000).
We previously have identified the mutation
MSH2*1906GrC, which causes a substitution of pro-
line for alanine at amino acid residue 636 (A636P)
(Yuan et al. 1999). Here, we describe the genetic char-
acterization of this mutation. We also conducted mu-
tation-frequency studies in unselected series of Ashke-
nazi Jewish individuals with colorectal, endometrial,
breast, or ovarian cancer, ascertained in North Amer-
ica and Israel, as well as in an ongoing, large popula-
tion-based case-control study in northern Israel. We
have also estimated the magnitude of the contribution
of this mutation to HNPCC in the Ashkenazi Jewish
population.
Subjects, Material, and Methods
Nonsystematic Series of Mutation Carriers
The MSH2*1906GrC mutation was first identified
in an Ashkenazi Jewish woman from a typical family
with HNPCC (Yuan et al. 1999). The family fulfilled
the Amsterdam criteria, as described elsewhere (Vasen
et al. 1991). At approximately the same time, the mu-
tation was independently identified in North America,
Europe, and Australia, in unrelated individuals, and it
was first posted on the Web site of the International
Collaborative Group on Hereditary Non-Polyposis Co-
lorectal Cancer (see the “Choose a Mutation Database”
Web page), by Bressac de Paillerets and colleagues, in
1998. Analysis of the mutant protein in a yeast-based
assay indicated that the mutation compromises MSH2
function (Yuan et al. 1999). In the following 3 years,
probands from several other North American, Euro-
pean, Israeli, and Australian kindreds with an excess of
colorectal or other HNPCC-related cancers were found
to carry this mutation (table 1). These probands and
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Figure 1 Representative families with the MSH2*1906GrC mutation. Carriers of MSH2*1906GrC are indicated by “/”; tested non-
carriers are indicated by “/”; all other individuals are untested. Notably, none of these families fulfil the Amsterdam criteria but, nevertheless,
a priori are very likely to carry germline mutations in mismatch-repair genes.
other family members were studied further. All these
individuals were seen in cancer-genetics clinics in various
settings in the nine centers that contributed case subjects
to this study. All clinic and population studies were con-
ducted under the auspices of protocols approved by In-
stitutional Review Boards.
Having identified the MSH2*1906GrC mutation in
these selected families, we wished to establish more
firmly its disease-causing nature and to determine its
frequency in (a) families with a high probability of car-
rying a germline mutation in a mismatch-repair gene,
(b) unselected individuals with HNPCC-related cancers
(colorectal, ovary, and endometrial), (c) a population-
based series of individuals with colorectal cancer and
age- and sex-matched control individuals, (d) women
with breast cancer who had a family history of colorectal
or ovarian cancer, and (e) unaffected North American
control individuals. By studying all of these groups, we
sought to determine, in a comprehensive fashion, the
contribution that this mutation makes to HNPCC-re-
lated cancers in the Jewish population and to establish,
at least in part, the phenotypic range of expression of
this mutation.
Because of the different types of ascertainment criteria,
Foulkes et al.: A Founder Mutation in MSH2 1399
Figure 2 Immunohistochemical staining of MSH2 (A) and MSH6 (B), in the woman in family 3 who has colorectal cancer and carries the
MSH2*1906GrC mutation (tables 1 and 2) and in control samples from colorectal tumors in which MSH2 (C) and MSH6 (D) are expressed.
The colonic adenocarcinoma is moderately differentiated, with relatively well-formed glands infiltrating the stromal tissue. Positive immunoreactivity
with antibodies to MSH2 and MSH6 is represented by the presence of brown staining in the nuclei. There is a complete absence of nuclear staining
of both MSH2 and MSH6 in the tumor cells, whereas a few scattered small lymphocytes show brown labeling in their nuclei (arrow). The presence
of nuclear staining in lymphocytes serves as an internal positive control. The stain for MSH6 shows some cytoplasmic labeling both in the tumor
cells and in some stromal cells. The significance of such cytoplasmic staining in this patient is unclear but is likely a reflection of nonspecific
background staining.
we made efforts to ensure that none of the families in-
cluded in the different series were identical or closely
related. These efforts included checking last names and
examining pedigrees. Except for the Memorial Sloan-
Kettering Cancer Center (MSKCC) series (discussed
below), none of the persons who carried the
MSH2*1906GrC mutation whose identities were
known to us are closely related. Carriers identified in
anonymized series may or may not be related to persons
in the patient-identified series.
Hospital-Based Series
Families with colorectal cancer.—At MSKCC, 109
kindreds were ascertained during 1995–2001. Probands
were systematically ascertained either by a family-his-
tory questionnaire administered to persons visiting the
gastrointestinal endoscopy and oncology clinics, by per-
sonal interview of persons undergoing surgery for co-
lorectal cancer, or by referrals to the Clinical Genetics
service. To the extent possible, the relevant cancer di-
agnoses identified by the proband were confirmed by
obtaining pathology reports or death certificates. Of the
109 families ascertained, 37 were Ashkenazi Jewish; 12
of these 37 families fulfilled the Amsterdam criteria for
HNPCC, whereas the other 25 families were HNPCC-
like, defined as containing three or more cases of colo-
rectal cancer occurring at any age in first- or second-
degree relatives. In 6 of the 109 families in which there
were either two or more individuals with adenomatous
polyps or at least one individual with colorectal cancer
diagnosed before age 50 years, the presence of an ade-
nomatous polyp was counted as a surrogate for a co-
lorectal cancer. At least one affected individual from each
of these 37 families was tested for the MSH2*1906GrC
mutation. Five of these 37 families were also ascertained
in the case-series part of the study, but they were not
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Table 3
MSH2*1906C Data: Frequency, Family History of Cancer,
and Age at Diagnosis, in the MECC Study
A. Consecutive Colorectal Cancer Cases
NO. OF CASES/NO. OF
CONTROL INDIVIDUALS
Ashkenazi
Jews
Sephardic
Jews OTHERa TOTAL
1906C 3/0 0/0 0/0 3
WT sequence 683/566 159/185 76/78 1,747
Total 686/566 159/185 76/78 1,750
B. Family History of Colorectal or Endometrial Cancer in a
First-Degree Relative, in Ashkenazi Jews with Colorectal
Cancerb
Positive
Family
History
Negative
Family
History Totalc
1906C 2 1 3
WT sequence 79 571 650
Total 81 572 653
C. Age at Diagnosis in Ashkenazi Jews with Colorectal
Cancer
Age at
Diagnosis
!60 years
Age at
Diagnosis
60 years Totald
1906C 2 1 3
WT sequence 77 606 683
Total 79 607 686
a Arab (107), Bedouin (1), Druze (18), and “non-Arab/
non-Jew” (28).
b Family history was not available for 33 cases.
c (by Fisher’s exact test, two sided).Pp .042
d (by Fisher’s exact test, two sided).Pp .036
counted twice in the total number of identified families
(see previous section and results below). In addition, 25
individuals from the 37 families (1 individual per fam-
ily—10 from HNPCC and 15 from “HNPCC-like” fam-
ilies) were tested for microsatellite instability (Boland et
al. 1998).
Consecutive cases of patients with colorectal can-
cer.—Two series were studied. The first series comprised
108 Ashkenazi Jewish patients with incident colorectal
cancer who were treated at MSKCC. The DNA samples
were anonymized after sex, age, and ethnicity had been
recorded, and, therefore, personal identifiers and family-
history information are not available for these 108 in-
dividuals. A total of 41 women and 67 men were tested.
The mean age at diagnosis was 61.0  11.7 years. The
second series comprised 564 patients with histopatho-
logically proven colorectal cancer who were diagnosed
and treated at Elias Sourasky Medical Center in Tel Aviv,
during January 1998–December 2001, and who were
eligible for participation. Clinical data regarding family
history of cancer, age at diagnosis, and relevant tumor-
associated data were obtained from a personal ques-
tionnaire, review of pathological reports, and data from
medical records. Of these 564 patients, 355 were Ash-
kenazi Jews and 209 were non-Ashkenazi Jews. All were
screened for the presence of the MSH2*1906GrC mu-
tation, and, therefore, in the two hospital series, 463
Ashkenazi Jewish individuals with colorectal cancer
were tested for this mutation.
Historical cohort of incident HNPCC-related can-
cers.—DNA extracted from paraffin-embedded tumors
from two historical cohorts of Ashkenazi Jewish pa-
tients, one with ovarian carcinoma ( ) and thenp 83
other with endometrial cancer ( ), ascertained atnp 197
MSKCC were resequenced for the MSH2*1906GrC
mutation. The clinicopathological characteristics of the
cancers in these two cohorts have been described else-
where (Boyd et al. 2000; Levine et al. 2001). Women
known to be carrying an Ashkenazi Jewish founder mu-
tation in either BRCA1 or BRCA2 were not included in
this study.
Familial breast cancer.—Two hundred seventy-one
Ashkenazi Jewish breast cancer probands who had a
family history of colorectal cancer or ovarian cancer
were collected from various centers in the United States
during the course of studies of breast cancer genetics. In
the present study, these samples were analyzed for the
MSH2*1906GrC mutation, at the Division of Medical
Genetics, University of Washington, Seattle. The criteria
for inclusion in this study were as follows: (a) wild type
(WT) for the three founder Ashkenazi Jewish BRCA1/
2 mutations, genotyped by sequencing (no other
BRCA1/2 genotyping was performed) and (b) at least
one case of ovarian or colorectal cancer occurring at any
age in first-degree relatives.
Population-Based Studies
The Molecular Epidemiology of Colorectal Cancer
(MECC) study is a population-based case-control study
of colorectal cancer in northern Israel. Residents of the
northern and Haifa districts of Israel who are diagnosed
with histopathologically confirmed, incident colorectal
cancer between March 31, 1998, and December 31,
2002, are eligible as cases. Population-based control in-
dividuals are identified from the Clalit Health Services
database and are individually matched to cases by exact
year of birth, gender, and clinic. Interim data for 921
cases and 829 control individuals from this ongoing
case-control study were available for the present anal-
ysis. All were screened for the MSH2*1906GrC mu-
tation. Of the 921 cases, 686 were Ashkenazi Jews; of
the 829 control individuals, 566 were Ashkenazi Jews.
The New York Cancer Project (NYCP) is an ongoing
cohort study with current ascertainment of 118,000 vol-
unteers (ages 30–69 years) who live in the New York
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Figure 3 Schematic representation of MSH2 and surrounding regions of chromosome 2. Marker loci and genetic distances are shown. This
map is based on information provided by The Genome Database and the National Center for Biotechnology Information (see the “Single Nucleotide
Polymorphism” Web page). We used the “BLAST Search Genome” Web page (August 2001 freeze) of the University of California, Santa Cruz, to
obtain the relative genetic positions of these markers. The relative positions of some markers have been published elsewhere (Green et al. 1994;
Desai et al. 2000), but some of that positional information was erroneous. Single-nucleotide polymorphisms (SNPs) were identified by use of “The
SNP Consortium Ltd.” Web site. The MSH2 map was designed in accordance with data provided by the ICG-HNPCC. Intragenic markers have
been described elsewhere (Desai et al. 2000). Alongside the vertical portion of the ideogram, we have indicated the positions of markers, according
to the recombination map presented by Kong et al. (2002). Note that the positions of D2S391 and Rs1374749 with respect to surrounding markers
are uncertain. According to data available at the Golden Path Web site (see the “UCSC Genome Informatics” Web page), Rs1374749 is centromeric
of D2S391, whereas according to the recombination map presented by Kong et al. it is telomeric; Kong et al.’s recombination map also places
Rs919883 telomeric of D2S391. There are discrepancies between the recombination map and the physical map presented by Kong et al. If the true
map order is tel–D2S391-Rs1347479-Rs896213-Rs919883-cen (based primarily on physical data), then all markers from MSH2 up to and including
Rs1347479 are completely conserved, whereas D2S391 and markers beyond it are not. At this time, it is not possible to synthesize all of the
available mapping data into one consistent marker order. For further details, see the Electronic-Database Information and Results sections.
Metropolitan area. Subjects were enrolled at seven hos-
pitals and six community centers in New York City, and
they provided consent for genetics studies on deidentified
DNA samples prepared from blood. We obtained sam-
ples from a subset of persons who are healthy, unaffected
by cancer, and self-identified as Jewish. At the time of
acquisition of the DNA specimens, there were 2,172
Jews enrolled in the NYCP; in the present study, we used
DNA samples from 1,022 of these individuals.
Pathological Evaluation and Immunohistochemical and
Microsatellite-Instability Analyses
Pathological evaluation and immunohistochemis-
try.—Centralized pathology review was not performed,
but each cancer in individuals subjected to mutation
analysis was verified at the referring center. When tissue
was available, immunohistochemistry was performed,
with modifications of a protocol described elsewhere
(Marcus et al. 1999).
Microsatellite instability.—Assays were performed on
microdissected DNA from paraffin-embedded blocks, by
use of a consensus panel of markers, as described else-
where (Boland et al. 1998). Radiolabeled PCR products
amplified by use of the “Bethesda panel” of markers
were scored for the appearance of novel locus-specific
bands in the tumor but not in the DNA of normal tissue.
A tumor was scored as MSI-H when the proportion of
successfully typed loci exhibiting novel bands was .3;
a tumor was scored as non–MSI-H when the proportion
was !.3
Molecular Analyses
Characterization of the MSH2*1906GrC muta-
tion.—The MSH2*1906GrC mutation was originally
identified in the clinical and research laboratories of par-
ticipating institutions, by several different methods. All
available DNA samples were resequenced in the Molec-
ular Diagnostics Laboratory at Sir M. B. Davis-Jewish
General Hospital, by the Visible Genetics OpenGene sys-
tem (Visible Genetics). The primer pairs used for se-
quencing the PCR-amplified exon 12 of MSH2 are
shown in the “Methods for Detection of the
MSH2*1906GrCMutation” section and table A1, both
in the Appendix, in the online version of this article. For
the sequencing procedure, reagents from Visible Genetics
were used. In brief, an aliquot of the PCR product (3–8
ml, depending on the yield) was mixed with sequencing
buffer, dimethyl sulfoxide, Cy5.5 M13 primer, water,
and Thermosequenase enzyme (Amersham), according
to instructions included as an insert to the kit. This mix-
ture was then distributed (5 ml/tube) into four tubes (la-
beled “A,” “C,” “G,” and “T”) containing 3 ml of the
termination mix. The mixture was then cycled for 35
cycles, on a thermal cycler, as follows: 94C for 30 s,
55C for 30 s, and 70C for 45 s. The thermal cycling
was initiated with a 2-min denaturation step at 94C
and was terminated with a 5-min extension step at 70C.
At the end, 6.0 ml of the loading dye (containing for-
mamide) was added to each of the four tubes, to stop
the sequencing reaction. The sequencing samples were
then denatured at 80C for 3 min and then immediately
were placed on ice. Two microliters was then loaded
onto a 6% acrylamide gel containing 6 M urea. Data
acquisition and base calling were achieved by use of
Gene Objects software (Visible Genetics).
Denaturing high-performance liquid chromatography
(DHPLC) was also used to identify mutations in DNA
prepared from blood. A complete description of the
methods used is provided in the “Methods for Detection
of the MSH2*1906GrC Mutation” section in the Ap-
pendix, in the online version of this article.
For the unselected series of endometrial and ovarian
cancers, for which the source of DNA was archival path-
ological tissue, direct sequencing was used to detect the
mutations, as described above. For the University of
Washington series of breast cancer cases, screening for
the MSH2*1906GrC mutation was performed by SSCP
using sense primer 5′-CCAATGCAGACACTCAATGA-
TGTG-3′ and antisense primer 5′-CCACAAAGCCCAA-
AAACCAGG-3′. An allele-specific oligohybridization
Figure 4 Schematic map of chromosome 2, showing extent of potential haplotype sharing. Sixteen unrelated families were studied. The
position of MSH2 is indicated, and the positions of markers are as shown in figure 3. “D” denotes distance (in Mb). The double-headed vertical
arrows indicate the extent of the possible haplotype sharing in different groups of mutation carriers, and the ends of the arrows indicate the last
marker that is conserved in the indicated fraction of probands studied; for example, probands from 9 of 15 families share a haplotype that could
extend over a maximum of ∼10.3 Mb. The proportion of families sharing the same haplotype increases from left to right. For details, see the text.
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Table 5
Frequency of MSH2*1906GrC in Ashkenazi Jewish Individuals with Cancer
STUDY GROUP OR HOSPITAL
SITE OF
CANCER ASCERTAINMENT SCHEME
NO. OF CASES
1906C/Total (%)
1906C Diagnosed
at Age !60 years/
Total 1906C (%)
Mount Sinai Hospital, Toronto Colorectum Incident cases, hospital based 0/196a 0/23b
MSKCC Colorectum Incident cases, hospital based 1/108 (.92) 1/42 (2.39)
Northern and Haifa Districts, Israel Colorectum Incident cases, population based 3/686 (.44) 2/75 (2.67)
Elias Sourasky Medical Center, Tel Aviv Colorectum Incident cases, hospital based 4/355 (1.1) NA
MSKCC Ovary Incident cases, hospital based 0/83 0/22
MSKCC Endometrium Incident cases, hospital based 2/197 (1.02) 0/55
University of Washington, Seattle Breast Part of nationwide BRCA1/2-related studies 0/271 NA
a Source: Yuan et al. (1999).
b Source: Dr. M. Redston (personal communication).
assay was optimized to screen for MSH2*1906GrC
mutations among cases and control individuals in the
large population-based series. A complete description of
the methods is provided in the “Methods for Detection
of the MSH2*1906GrC Mutation” section and table
A1, both in the Appendix, in the online version of this
article.
Haplotype analysis.—Haplotype analysis was per-
formed on each individual by use of single-nucleotide
polymorphisms (SNPs) and microsatellites on chromo-
some 2. The tetranucleotide repeat (TTTA, TTTG, or
TAAA) and dinucleotide repeat (CA-1, CA-2, or CA-3)
microsatellites were visualized by fragment-size analysis
by the OpenGene System. The PCR products for these
markers were diluted fivefold with sterile water. We added
5 ml of loading buffer to 1 ml of the diluted PCR product
and denatured the mixture at 80C for 3 min and then
loaded 2 ml onto a 6% polyacrylamide gel. The other
microsatellite markers—D2S2331, D2S391, D2S2306,
D2S123, and D2S2227—were amplified by PCR using
[35S]-dATP. PCR products were separated on denaturing
acrylamide gels and were visualized by autoradiography.
The SNPs Rs896213 and Rs1544689 were analyzed by
sequencing using a Cy5.5 DEAZA dye sequencing kit
(Visible Genetics) and the OpenGene System; the other
SNPs—Rs919883, Rs868542, and Rs1374749—were
amplified by PCR, and the products were digested by
restriction enzymes SfaNI, BsmI, and PmlI (New En-
gland Biolabs), respectively, according to the manufac-
turer’s instructions. Primer sequences and PCR conditions
are shown in the “Methods for Detection of the
MSH2*1906GrC Mutation” section and table A1, both
in the Appendix, in the online version of this article.
Somatic-Cell Hybridization
Epstein-Barr virus–transformed cells were available
from an individual in family 7 (table 1). Somatic-cell
hybrids containing a maternally or paternally derived
chromosome 2 were obtained from GMP Genetics.
Statistical Analyses
Association analyses.—Odds ratios were calculated by
use of 2 # 2 tables, and Gart’s method was used for
the 95% CI (Fleiss 1981). P values reported are the
results of two-tailed Fisher’s exact tests, because some
of the cells had expected counts of !5. The frequency
of the MSH2*1906GrC mutation in different sub-
groups was estimated by the sign test, and exact 95%
CIs were calculated for the proportions by the Clopper-
Pearson method. Statistical analyses were performed by
SAS version 8.00 (SAS Institute).
Frequency of haplotypes in the Ashkenazi Jewish pop-
ulation.—Because the number of Ashkenazi Jewish fam-
ilies available was not large, haplotypes were recon-
structed by the program PHASE (Stephens et al. 2001),
which uses Bayesian methods to predict the haplotype
distribution, conditional on observed genotypes. The al-
gorithm is implemented by Gibbs sampling, which is a
type of Markov chain–Monte Carlo algorithm (Gilks et
al. 1996). For nine markers (PRMT to CA-2 [Desai et
al. 2000]; see the “Methods for Detection of the
MSH2*1906GrCMutation” section and table A1, both
in the Appendix, in the online version of this article),
we used DNA from 54 Ashkenazi Jews from Israel (ob-
tained from the National Laboratory for the Genetics
of Israeli Populations, Tel Aviv University) to construct
the haplotypes. We seeded the program with 12 known
haplotypes. We used both the 11 unlinked haplotypes
that were established by analysis of the individuals car-
rying the MSH2*1906GrC mutation and the haplotype
associated with the mutation itself. Ten simulations were
run from different starting points, and the results were
used to estimate the frequency of the linked haplotype
in the Ashkenazi Jewish population.
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Results
MSH2*1906GrC Occurs in Ashkenazi Jews with
Colorectal and Other Cancers
In addition to the first reported kindred, a total of 24
individuals from 14 unrelated families were initially
identified, at various centers in North America, Europe,
and Australia, as being carriers of the MSH2*1906GrC
mutation. These cases were not identified during the
course of specific mutation-prevalence studies but were
seen in clinical cancer-genetics clinics. Subsequently, it
became apparent that, of these 15 originally ascertained
families, 5 (families 2–4, 8, and 9; table 1) were also
represented in the systematic series of families with
HNPCC ascertained at MSKCC (families 175, 1580,
1692, and 2650 are listed in table 2, and families 1431
and 2475 are listed in table A2, in the Appendix in the
online version of this article). We have included these
five families in the analysis of families with HNPCC but
have not counted them twice in the final totals. In 12
of these 15 families, the probands identified themselves
and their parents as Ashkenazi Jewish; in 2 families,
ethnic origins could not be ascertained; in 1 family, the
family’s last name and country of origin suggest Jewish
origins. The clinicopathological features of the cancers
and the family histories of the probands (including the
initial proband from MON702) are shown in table 1.
Particularly noteworthy is the wide range of cancers seen
in carriers of the MSH2*1906GrC mutation. Although
the Amsterdam criteria were not met in all families, the
cancer histories in all the families were suggestive of
mismatch-repair–gene mutations. For example, family 2
did not fulfil these criteria because cancer was said to
arise in the bladder (rather than in the ureter) in the
paternal grandfather of the proband. In fact, this family
is the first reported kindred with a MSH2 mutation and
with three generations of individuals diagnosed with
transitional cell carcinoma of the urothelium. In family
5, the proband was diagnosed with six separate cancers:
metachronous colorectal cancer, metachronous urothe-
lial transitional cell carcinoma, a soft-tissue sarcoma,
and finally, at the age of 78 years, a glioblastoma mul-
tiforme (fig. 1). One individual in family 14 was diag-
nosed with seven cancers (colorectal cancer on three sep-
arate occasions, ureteric cancer twice, and stomach and
bladder cancer). The proband in this family also had a
ureteric cancer (table 1).
MSH2*1906GrC Is Associated with Microsatellite
Instability, Absence of MSH2 Protein, and an
Alteration in MSH2 Crystal Structure
When tumor tissue was available, testing for micro-
satellite instability was performed. All 15 colorectal can-
cers tested (as well as 1 ovarian cancer and 1 endometrial
cancer) exhibited an MSI-H phenotype (table 1). In all
10 tumors examined by immunohistochemistry, MSH2
protein (table 1 and fig. 2) was highly reduced or absent.
When MSH6 was also assessed (fig. 2), this protein was
also missing. This latter finding is not unexpected, be-
cause together MSH2 and MSH6 form a complex. The
crystal structure of MutS has recently been determined
in Thermophilus aquaticus (TAQ), by Obmolova et al.
(2000), and in Escherichia coli, by Lamers et al. (2000).
Position 636 is only two codons from the highly con-
served amino acid motif (i.e., RH) that appears to be
important for interdomain interactions. The alanine it-
self is not conserved either in yeast MSH2, MSH3,
MSH4, MSH5, or MSH6 or in human MSH3 or MSH6.
Nevertheless, in TAQ, the equivalent codon, 555, is for
alanine. Altering the crystal structure of TAQ in silico,
we showed that the homologous mutation A555P in-
terferes with the carbonyl group of neighboring phe-
nylalanine. This change probably affects ATP binding
or protein/protein interactions (W. Yang, personal com-
munication). Taken together, these findings suggest
strongly that the MSH2*1906GrC mutation is disease
causing.
MSH2*1906GrC Is an Important Cause of HNPCC in
the Ashkenazi Jewish Population
We wished to estimate what proportion of autosomal
dominant familial colorectal cancer could be caused by
this mutation. To do this, we screened 37 affected in-
dividuals from MSKCC who met either the HNPCC
criteria ( ) or the HNPCC-like criteria ( );np 12 np 25
of the 37 individuals tested, 6 (mutation prevalence .16;
95% CI .06–.32) carried the MSH2*1906GrC muta-
tion. In the 12 families that met the Amsterdam criteria
(table 2), the mutation prevalence was .33 (95% CI
.10–.65). The mutation was found in one of the fam-
ilies meeting the HNPCC-like but not the Amsterdam
criteria (see the “Analysis of the MSH2*1906GrC Mu-
tation in New York Families with Colorectal Cancer”
section and table A2, both in the Appendix, in the on-
line version of this article). Of the 12 families with Am-
sterdam criteria–fulfilling HNPCC, 6 carried a muta-
tion in either MSH2 or MLH1; consequently, the four
MSH2*1906GrC mutations accounted for .67 (95%
CI .22–.96) of all identified mutations in Ashkenazi Jew-
ish families with HNPCC that fulfills the Amsterdam
criteria.
Frequency of the MSH2*1906C Allele in Population-
Based Cases and Control Individuals
To determine the frequency of the 1906C allele in an
unselected series of Jewish individuals with or without
colorectal cancer, we genotyped 1,750 Israeli individuals
(including 686 Ashkenazi Jewish cases and 566 Ash-
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kenazi Jewish control individuals) ascertained in the on-
going MECC study. The ethnic breakdown and results
are shown in table 3. Among 686 Ashkenazi Jewish co-
lorectal cancer cases, we identified 3 carriers of the
1906C allele; no carriers were identified among 566 Ash-
kenazi Jewish control individuals. Thus, in this large
unselected series, 0.44% (95% CI 0.09%–1.27%) of
colorectal cancers occurring in Ashkenazi Jewish indi-
viduals is attributable to the 1906C allele. The allele was
not in statistically significant excess in Ashkenazi Jews
with colorectal cancer compared with Ashkenazi Jewish
control individuals ( ) (table 3A). To further es-Pp .26
timate the population frequency of this mutation, we
tested 1,022 Jewish individuals enrolled in the NYCP.
No carriers were detected; thus, 0/1,588 Ashkenazi Jew-
ish people carry this allele (the upper limit for the 95%
CI is 0.23%).
Dichotomizing the study group on the basis of either
positive family history (table 3B) or age at diagnosis (table
3C) reveals the influence that the mutation has on the
presentation of colorectal cancer in carriers of the 1906C
allele. The absence of this mutation in non–Ashkenazi
Jewish individuals with colorectal cancer and/or a family
history consistent with HNPCC (table 3A) does not prove
that this mutation is absent from other populations, but
it does appear that the mutation is likely to be very rare
in non–Ashkenazi Jewish populations.
Frequency of the MSH2*1906C Allele in Hospital-
Based Consecutive Series of Cases of Colorectal
Cancer
A series of 564 individuals with colorectal cancer who
were diagnosed in Tel Aviv were screened for the pres-
ence of the MSH2*1906GrC mutation; of these 564,
355 (63%) were Ashkenazi Jews and 209 were of non-
Ashkenazi Jewish origins. Four mutation carriers were
detected, all of Ashkenazi Jewish origin, whose ancestors
lived in either Poland ( ) or Russia ( ). Thus,np 2 np 2
in this hospital series, 1.1% (95% CI 0.31%–2.9%) of
Israeli Ashkenazi Jews with colorectal cancer carry the
MSH2*1906GrC mutation. Two of the four cases were
diagnosed at age !60 years. Two of the four affected
carriers also had previous colonic polyps, and, of three
individuals who had details of their family history, two
reported first-degree relatives with colorectal cancer. The
frequency of the 1906C allele was also estimated in 108
incident cases of colorectal cancer in Ashkenazi Jews
who had surgery at MSKCC. We identified one carrier
in this series, an affected man diagnosed with colorec-
tal cancer at age 28 years. This mutation carrier was
one of only five individuals in this series who were di-
agnosed at age !40 years, compared with no carriers
identified in the remaining 103 tested ( ). ThisPp .046
finding further supports the contention that the
MSH2*1906GrC mutation causes early-onset colorec-
tal cancer and is a rare allele in the Ashkenazi Jewish
population.
Frequency of the MSH2*1906C Allele in Unselected
Series of Women with HNPCC-Related Cancers
To characterize the contribution that the MSH2*
1906GrC mutation makes to adenocarcinoma of the
endometrium, ovary, and breast, we studied three series
of women. Two of these series were from MSKCC—one
series comprised 197 Ashkenazi Jewish women diag-
nosed with endometrial adenocarcinoma from Decem-
ber 1986 to August 1998, and the other series comprised
83 Ashkenazi Jewish women diagnosed with ovarian
cancer at the same institution during the same period.
Two (1.02%; 95% CI 0.1%–3.6%) women with en-
dometrial adenocarcinoma (diagnosed at ages 72 and 76
years) were found to carry the MSH2*1906GrC mu-
tation, whereas none of the 83 women with ovarian
cancer (mean age at diagnosis, 64.6 years; SD 11.8 years)
carried this mutation (95% CI 0%–4.3%). The ages at
diagnosis of endometrial adenocarcinoma are older than
the mean age for this series (66.3 years; SD 11.1 years).
A third series consisted of 271 U.S. Ashkenazi Jewish
breast cancer probands who had a family history of ei-
ther colorectal cancer or ovarian cancer and who had
been collected from various centers in the United States.
No mutations were identified in these women (95% CI
0%–1.4%).
Haplotype Analysis
To determine the haplotype associated with the chro-
mosome bearing the MSH2*1906GrC mutation in one
individual (from family 7) (tables 1 and 4), somatic-cell
hybrids carrying only the mutation-bearing human chro-
mosome 2 were analyzed at polymorphic loci spanning
an ∼16-Mb region that flanks MSH2 (fig. 3). An 18-
marker haplotype was constructed. This haplotype con-
sisted of 7 SNPs and 11 polymorphic microsatellite loci
(see the “Methods for Detection of theMSH2*1906GrC
Mutation” section and table A1, both in the Appendix,
in the online version of this article). Using human-genome
sequence data recently made available at the “Golden
Path” Web site of the University of California, Santa Cruz
(see the “UCSC Genome Informatics” Web page), we
mapped previously reported markers CA-1, CA-2, and
CA-3 (Desai et al. 2000) as being situated 3′ of MSH2.
Figure 3 illustrates the physical distances, in base pairs,
between each marker, as well as these markers’ relation-
ship to MSH2. On the basis of the Golden Path Web site’s
map order of August 2001 (see the “UCSC Genome In-
formatics” Web page), the most likely order of the loci
that we tested is tel–D2S2331–D2S2306–Rs868542–
Rs896213–D2S391–Rs1374749–D2S2227–Rs919883–
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[5′MSH2–TTTA repeat–TTTG repeat–TAAA repeat–
E105′–E103′–1906C/3′MSH2]–CA-3 repeat–CA-1 repeat–
CA-2 repeat–Rs1544689–D2S123–cen (table 4). The
1906C-bearing haplotype in individual JHU SG (family
7) (tables 1 and 4) is tel-4-3-*-A-2-A-3-G-[288-255-177-
A-G-C]-139-143-250-C-6-cen (the alleles are given in the
same order as are the loci, the intragenic markers are
indicated by square brackets, the mutation is in boldface,
and the asterisk indicates that this locus has no link-
age information in this individual; details are shown in
table 4).
The genotypes from representative mutation carriers
are shown in table 4. Markers from the distal flanking
marker D2S2306 to the proximal marker CA-2 were
shared by 9 of 15 probands for whom we had data on
all markers; this distance is ∼10.3 Mb (fig. 4). In indi-
vidual JHU SG, in whom we were able to study each
chromosome separately, the mutation occurs on a hap-
lotype where the allele at D2S3206 is 3—rather than 4,
which appears to be linked in all other families tested.
If the linked haplotype truly does break down some-
where between Rs896213 and D2S2306 but extends to
CA-2 on the centromeric side of MSH2, then the linked
region is 3.2 Mb in length; this region is shared by 12
of 15 probands. A breakdown distal to Rs896213 is
likely, because 2 of 13 tested individuals did not share
the common haplotype at SNP marker Rs868542, which
is only 167 kb telomeric of Rs896213. In a region closer
to the gene, two individuals (S-M112 and 8080894) (ta-
ble 4) do not carry the linked allele (i.e., allele 2) at
D2S391. Because this is a microsatellite marker, it is
possible that this represents a marker mutation (these
individuals are 3,4 and 3,3, respectively, at this locus).
More conservatively, if one considers that the haplotype
breaks down here but extends from Rs1374749 proxi-
mally to CA-2, then the linked region is 2.03 Mb in
length (seen in 14 of 15 probands; fig. 4). It can be seen
in table 4 that alleles for the centromeric markers CA-
3 and CA-2 are different in MON702 compared with
all other mutation carriers, so, conservatively, the linked
haplotype ends !95 kb 3′ of MSH2. Therefore, the eight-
marker haplotype from Rs1374749 to the mutation it-
self (A-3-G-288-255-177-A-G) is shared by all 14 of the
families in which all the markers were tested. In this
case, the minimum linked region in this study is ∼1.91
Mb long (figs. 3 and 4). Because, in two families,
Rs1374749 could not be tested in probands, all 16 pro-
bands share a slightly smaller interval, ∼1.33 Mb (fig.
4). We checked the allele frequencies of 15 of the markers
used in this study, to establish whether the linked alleles
were common in the Jewish population. In 48–70 chro-
mosomes from unaffected Ashkenazi Jewish individuals,
the allele frequencies for the linked markers telomeric
to the gene (fig. 3) were as follows: D2S391, .193;
Rs1374749, .52; D2S2227, .276; and Rs919883, .397.
Only at Rs1374749 was the linked allele the most com-
monly observed allele in the control individuals studied.
Statistical tests show that, for extragenic markers
D2S2306, Rs896213, D2S391, Rs919883, CA-3, CA-
1, and CA-2, the linked allele is statistically significantly
more frequent in mutation carriers than in control in-
dividuals ( ; data not shown). In sum-Pp .0001–.04
mary, the shortest linked region, seen in all 16 probands
tested, is 1.33 Mb, whereas the longest possible region
of sharing is ∼10.3 Mb, but both microsatellite and SNP
results make this degree of sharing unlikely (table 4).
We used the PHASE program to estimate the fre-
quency of the haplotype bearing the MSH2*1906GrC
mutation in the Ashkenazi Jewish population. The sta-
tistical basis of this new method is discussed briefly in
the Subjects, Material, and Methods section. We geno-
typed 54 randomly selected unaffected individuals, at
six intragenic markers, as well as at three 3′ flanking
markers—CA-1, CA-2, and CA-3 (table 4 and fig. 3).
By seeding the program with (a) the identified linked
intragenic haplotype and (b) 11 other phased unlinked
haplotypes from individuals whose genotypes are shown
in table 4, we were able to predict with 90% probability
that four to six chromosomes (depending on the simu-
lation) in the 54 individuals carry the disease-linked in-
tragenic haplotype. None of these chromosomes carries
the MSH2*1906GrC mutation. This suggests that the
intragenic portion of the linked haplotype is present in
∼10% of unaffected Ashkenazi Jewish individuals but
is not associated with the disease-causing mutation.
However, no control chromosomes were predicted to
match the disease-associated haplotype when markers
CA-1, CA-2, and CA-3 were included in the analysis.
Discussion
In the present article, we have described the identifica-
tion and characterization of a founder mutation in
MSH2. This base-pair substitution, 1906GrC, results
in the alteration of the amino acid sequence from that
of alanine to that of proline. On the basis of segrega-
tion, MSI analyses, and a yeast assay (Andreutti-Zaugg
et al. 1997) in a single Ashkenazi Jewish family, we orig-
inally predicted that this mutation would be disease
causing, but we did not have sufficient data to be com-
pletely convinced of this (Yuan et al. 1999). The present
study, together with recent data reporting that the ad-
dition of a single human chromosome containing the
MSH2*1906GrC mutation did not correct mismatch-
repair deficiency in Msh2/ mouse cells (Marra et al.
2001), confirms that this variant is a bona fide disease-
causing mutation. Importantly, the immunohistochem-
ical data presented here show that the protein is unsta-
ble. The presence of this mutation in probands from 16
unrelated families (in which a total of 25 Ashkenazi
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Jewish individuals were tested) who all share the same
intragenic haplotype identify MSH2*1906GrC as the
first founder mutation in MSH2 in the Jewish popula-
tion. This mutation can be added to the list of founder
mutations that have been identified in Jews (Ostrer
2001).
Our previous report provided a clue that this muta-
tion might not be frequent in those with colorectal can-
cer, because we failed to identify this mutation in 196
Ashkenazi Jews with colorectal cancer. However, the
mean age at diagnosis in this series was 71.7 years
(range 39.8–92.1 years), and the age at diagnosis in 23
of these individuals was !60 years (M. Redston, per-
sonal communication); thus, few germline mutations
would be expected in this series. Only 15 of the 196
tumors showed MSI-H (Yuan et al. 1999), and, because
5%–15% of MSI-H colorectal cancer is due to germline
mutations in MSH2, in retrospect we now know that
our original study had insufficient power to detect this
founder mutation in MSH2.
We studied several series of unselected Ashkenazi
Jews with or without cancer, allowing us to estimate
the frequency of the MSH2*1906GrC mutation in
these groups. The results for those affected with cancer
are shown in table 5. Particularly noteworthy are the
findings in the three series of colorectal cancers—686
from northern Israel, 355 from Tel Aviv, and 108 from
MSKCC in New York. Three mutation carriers (diag-
nosed at ages 45, 52, and 75 years) were identified in
the northern-Israeli series, four (diagnosed at ages 36,
52, 60, and 69 years) in the Tel Aviv series, and one
(diagnosed at age 28 years) in the MSKCC series. Al-
though, clearly, the northern-Israeli and New York cases
and control individuals are not completely comparable,
it may be instructive to compare the frequency of the
mutation in a large series of Jewish cases and control
individuals. Thus, eight mutation carriers were identi-
fied among these 1,149 cases from northern Israel and
New York, and none were found among 1,588 control
individuals from the same two populations (Pp
). In our previous report, we identified no carriers.00095
among 196 Ashkenazi Jewish individuals with colorec-
tal cancer who were from Toronto. If we combine all
the results obtained in Ashkenazi Jews with colorectal
cancer, 8/1,345 (0.59%; 95% CI 0.26%–1.17%) af-
fected individuals carry this mutation. We do not have
the precise ages at diagnosis for the Tel Aviv series, but,
when the data from patients diagnosed at age !60 years
in the Toronto, MSKCC, and northern-Israel series are
combined, 3/140 (2.1%; 95% CI 0.44%–6.1%) indi-
viduals with colorectal cancer diagnosed at age !60
years carried this mutation (table 5). These results sug-
gest that the MSH2*1906GrC mutation cannot ac-
count for a large proportion of colorectal cancer; how-
ever, a significant fraction (10%–65%) of Amsterdam
criteria–fulfilling HNPCC occurring in the Ashkenazi
Jewish population is due to this single missense
mutation.
Family-based studies are, by their nature, biased to-
ward kindreds with numerous cases of cancer, but it is
nevertheless notable that the range of cancers seen in
mutation-bearing families is wide (table 1 and fig. 1)
and is in keeping with previous data that have suggested
that MSH2 mutations result in a cancer phenotype
broader than that resulting from MLH1 mutations (Va-
sen et al. 2001). Taken together, the spectrum of cancers
observed in carriers of the MSH2*1906GrC mutation
imply that vigilance will be required when such indi-
viduals are followed and that screening for cancer at all
potential sites will be difficult. The presence of uroth-
elial cancers in more than one member of several kin-
dreds (table 1) is particularly noteworthy.
In all 16 families genotyped at markers flanking
MSH2, there is a clear and complete breakdown of the
linked haplotype at D2S2331 (telomeric) and at
D2S123 (centromeric), resulting in a maximum shared
region that is ∼15.7 Mb; 14 families share a region
1.91 Mb (from Rs137479 to the mutation itself).
However, recent physical- and recombination-map data
(Kong et al. 2002) suggest that it is possible that
Rs1374749 is telomeric—not centromeric—to Rs896213,
as shown in figure 3. The precise position of D2S391
is also uncertain (fig. 3). If the order is as described in
the genetic map presented by Kong et al. 2002), then
it would slightly alter the length of the conserved hap-
lotype. However, we believe that the most parsimonious
interpretation of our data favors the map order indi-
cated in table 4 and figure 3.
It is interesting to note that, using the PHASE pro-
gram, we can predict that the intragenic haplotype will
be observed in ∼10% of Ashkenazi Jewish individuals
but that the program predicts that there would be no
unaffected individuals who share the haplotype once we
extend it beyond the boundaries of the gene. If we con-
sider haplotype, genotype, PHASE, and mutation-fre-
quency data, it is reasonable to conclude that the mu-
tation owes its origin to a founder who lived 200–
500 years ago. Consistent with these observations, the
size of the shared haplotype may extend as far as 10
Mb, historical recombination events having not yet bro-
ken the haplotypes into smaller segments. Moreover, if
the reason why other cancer-related founder muta-
tions in the Ashkenazi Jewish population, such as
BRCA1*187delAG are common (up to 1% of Ashke-
nazi Jewish individuals carry this mutation), is genetic
drift, then, clearly, mutation frequency can drift up or
down. Therefore, given the size of the Ashkenazi Jew-
ish population worldwide, the relative rarity of this mu-
tation may be a combination of recent origin and
chance.
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The exon 5 MSH2 mutation is a founder mutation
within Newfoundland, but it has several separate ori-
gins worldwide (Desai et al. 2000). Only three other
founders in mismatch-repair genes have been described
previously; all are in MLH1. de la Chapelle and col-
leagues described two different founder mutations in
MLH1, whose origins were placed at ∼400–1,075 years
ago (mutation 1) and at only 125–525 years ago (mu-
tation 2) (Moisio et al. 1996). In a study of 535 Finnish
individuals with incident colorectal cancer, 18 germline
MLH1 and MSH2 mutations were identified. Among
these 18 individuals, 13 carried a founder mutation (9
had mutation 1, and 4 had mutation 2). Thus, just test-
ing for these two founder mutations would detect 72%
of all mismatch-repair–gene mutations detected in this
series, and these two mutations account for 2.4% (95%
CI 1.3%–4.1%) of all colorectal cancer occurring in the
southeastern part of Finland (Salovaara et al. 2000).
These two mutations probably have a prevalence higher
than that of the MSH2*1906GrC mutation in the Ash-
kenazi Jewish population. The age of the third founder
MLH1 mutation could not be determined accurately,
because of the small number of available chromosomes
(Hutter et al. 1996), although more-recent investiga-
tions have suggested that this mutation is 400 years
old (P. Hutter, personal communication).
In the Ashkenazi Jewish population, several other
founder mutations have been identified in cancer-related
genes such as BLM, BRCA1, BRCA2, FANCC, and
APC. The heterozygote frequency of these alleles varies
from 1/16 for I1307K in APC to 1/107 for the 2281:
del6ins7 mutation in BLM (Ostrer 2001). The popu-
lation frequency of the MSH2*1906GrC mutation has
not been accurately determined in a single series. When
we combine the data presented here with those from
our previous study, in which we typed 100 control in-
dividuals, none of 1,688 unaffected Ashkenazi Jewish
individuals carry this mutation (upper 95% CI 0.22%,
or 1/458), suggesting that, in this population, it is rarer
than previously reported cancer-causing alleles. Larger
population-based studies will be required to more pre-
cisely estimate the population frequency of this allele.
In the present article, we have described the identi-
fication and characterization of a previously unrecog-
nized founder mutation in MSH2. This mutation, at
nucleotide 1906, codon 636, results in the substitution
of a proline for an alanine. Immunohistochemical anal-
yses of tumors that carry the A636P mutation show
that the mutant protein is unstable. Molecular modeling
suggests that this change results in steric hindrance and,
possibly, interference with ATP hydrolysis. The muta-
tion has been identified in 25 apparently unrelated fam-
ilies, most of which are known to be of Ashkenazi Jew-
ish origin. By screening for this mutation in several
unselected Ashkenazi Jewish populations, it has been
determined that the MSH2*1906GrC mutation is a
rare cause of colorectal cancer in this population but
that it probably accounts for 10% of all Amsterdam
criteria–fulfilling HNPCC in the Ashkenazi Jewish pop-
ulation. Because of this, it may be prudent, if Ashkenazi
Jewish ancestry is documented or suspected, to assay
for this mutation before proceeding to complete mo-
lecular analysis of MSH2 in Amsterdam crite-
ria–fulfilling kindreds in which a mismatch-repair–gene
mutation is suspected. This will be particularly useful
if immunohistochemistry documents a loss of MSH2
protein expression in colorectal cancer.
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